Trials / Completed
CompletedNCT06203158
Intestinal Epithelial Fucosylation Affects the Efficacy of Ustekinumab in Crohn's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The loss of response rate of ustekinumab(UST) is high, and the specific mechanism has not yet been elucidated. Molecular markers that can accurately predict the efficacy of UST are urgently needed to provide theoretical basis for guiding individualized treatment. Therefore, this study intends to explore the impact of intestinal epithelial fucosylation levels on the efficacy of UST in patients with Crohn's disease(CD), aiming to provide predictable molecular markers for UST to accurately treat CD.
Conditions
Timeline
- Start date
- 2023-12-26
- Primary completion
- 2024-02-10
- Completion
- 2024-02-28
- First posted
- 2024-01-12
- Last updated
- 2024-03-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06203158. Inclusion in this directory is not an endorsement.